<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00275561</url>
  </required_header>
  <id_info>
    <org_study_id>1488-05</org_study_id>
    <nct_id>NCT00275561</nct_id>
  </id_info>
  <brief_title>Topical Steroid Treatment for Eosinophilic Esophagitis</brief_title>
  <official_title>A Randomized Placebo-controlled Trial of Swallowed Fluticasone in Treatment of Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized controlled trial of swallowed fluticasone vs. placebo for eosinophilic
      esophagitis. Eosinophilic esophagitis is an inflammatory condition in which the wall of the
      esophagus becomes filled with large numbers of eosinophils, a type of white blood cell.
      Patients who have this condition have difficulty in swallowing (dysphagia) solid food.

      Prior to treatment the patients had biopsies of their esophagus and took questionnaires
      regarding their symptoms. Treatment was given for 6 weeks, after which biopsies were taken
      from the esophagus to measure any changes in the tissue from before treatment. The primary
      endpoint was improvement in dysphagia as measured by the validated Mayo Dysphagia
      Questionaire. Secondary outcomes included partial symptom response, and histologic (tissue)
      response to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a double-blind randomized placebo controlled trial to evaluate the effect of
      aerosolized fluticasone therapy on symptomatic dysphagia and histologic eosinophilia in
      adults newly diagnosed with eosinophilic esophagitis (EoE). Participants were randomized to
      receive aerosolized swallowed fluticasone 880 mcg bid or placebo inhaler swallowed bid for 6
      weeks.

      Four mid esophageal biopsies were obtained from 10 cm above the squamo-columnar junction;
      then formalin-fixed and stained with hematoxylin and eosin. All esophageal biopsies were read
      and scored by a single expert gastrointestinal pathologist. The formalin-fixed
      paraffin-embedded esophageal biopsies were retrieved and underwent standard major basic
      protein (MBP) immunofluorescence staining. All special stain slides were then read and scored
      by another pathologist. 24-hour urine was collected for free cortisol by the standard
      technique. The original endoscopy was performed before the patient was enrolled in the trial
      by standard clinical technique. The endoscopy post treatment was done in the clinical
      research unit by the principal investigator.

      Patients kept compliance logs that were reviewed at phone interviews at 2 and 4 weeks time
      and at the end of study evaluation. Ninety percent compliance was required for study
      inclusion.

      At the end of 6 weeks, a 24-hour urine cortisol was done, and patients underwent a repeat
      endoscopy while still on treatment. Mid-esophageal biopsies were obtained and evaluated for
      eosinophil density and mast cell degranulation. At this visit the patients returned dysphagia
      and side effects questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Response to Dysphagia</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measured by the Mayo Dysphagia Questionnaire, a validated 28 item instrument; 0=no dysphagia, higher levels indicate greater dysphagia severity. A complete symptom response was defined as an answer of &quot;no&quot; to the question &quot;In the past 2 weeks, have you had trouble swallowing, not associated with other cold symptoms (such as strep throat or mono)?&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Partial or Complete Response to Dysphagia</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measured by the Mayo Dysphagia Questionnaire, a validated 28 item instrument; 0=no dysphagia, higher levels indicate greater dysphagia severity. A complete symptom response was defined as an answer of &quot;no&quot; to the question &quot;In the past 2 weeks, have you had trouble swallowing, not associated with other cold symptoms (such as strep throat or mono)?&quot; A partial symptom response was defined as an answer of yes to the above question and a decrease in severity of at least 2 levels, or a decrease in frequency of at least 1 level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Histologic Response</measure>
    <time_frame>2 weeks</time_frame>
    <description>A complete histologic response was defined as &gt;90% decrease in mean eosinophil count/high powered field</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Fluticasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo inhaler swallowed bid for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <description>Aerosolized swallowed fluticasone 880 mg twice a day</description>
    <arm_group_label>Fluticasone</arm_group_label>
    <other_name>Flonase</other_name>
    <other_name>Veramyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo inhaler swallowed twice a day for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 20 eosinophils / hpf on biopsies from mid esophagus (hpf = high-powered field)

          -  Abnormal dysphagia questionnaire (question 1a &quot;yes&quot;, question 1c &gt; &quot;moderate&quot; and
             question 2 &gt; &quot;less than once a week&quot;) on Mayo Dysphagia Questionnaire.

        Exclusion Criteria:

          -  Clinical evidence of infectious process potentially contributing to dysphagia (e.g.,
             candidiasis, cytomegalovirus, herpes)

          -  Systemic or topical steroid therapy for any reason over the past 3 months

          -  Previous steroid treatment for Eosinophilic Esophagitis

          -  Intolerance to steroid therapy in the past

          -  Other cause of dysphagia identified at endoscopy (e.g., reflux esophagitis, stricture,
             web, ring, achalasia, esophageal neoplasm)

          -  Dilatation of esophagus at time of index endoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A. Alexander, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <reference>
    <citation>McElhiney J, Lohse MR, Arora AS, Peloquin JM, Geno DM, Kuntz MM, Enders FB, Fredericksen M, Abdalla AA, Khan Y, Talley NJ, Diehl NN, Beebe TJ, Harris AM, Farrugia G, Graner DE, Murray JA, Locke GR 3rd, Grothe RM, Crowell MD, Francis DL, Grudell AM, Dabade T, Ramirez A, Alkhatib M, Alexander JA, Kimber J, Prasad G, Zinsmeister AR, Romero Y. The Mayo Dysphagia Questionnaire-30: documentation of reliability and validity of a tool for interventional trials in adults with esophageal disease. Dysphagia. 2010 Sep;25(3):221-30. doi: 10.1007/s00455-009-9246-8. Epub 2009 Oct 24.</citation>
    <PMID>19856027</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2006</study_first_submitted>
  <study_first_submitted_qc>January 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2006</study_first_posted>
  <results_first_submitted>November 3, 2011</results_first_submitted>
  <results_first_submitted_qc>November 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2011</results_first_posted>
  <last_update_submitted>May 1, 2012</last_update_submitted>
  <last_update_submitted_qc>May 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <name_title>Jeffrey A. Alexander, M.D</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>Eosinophilic Esophagitis</keyword>
  <keyword>Fluticasone</keyword>
  <keyword>Dysphagia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult patients with a new diagnosis of eosinophilic esophagitis were recruited at the Mayo Clinic Rochester between 10/2005 and 12/2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluticasone</title>
          <description>Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo inhaler swallowed bid for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Travel</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Scheduling</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Family Issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluticasone</title>
          <description>Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo inhaler swallowed bid for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.5" lower_limit="19" upper_limit="59"/>
                    <measurement group_id="B2" value="35" lower_limit="20" upper_limit="57"/>
                    <measurement group_id="B3" value="37.5" lower_limit="19" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Food Impaction &gt; 5 minutes</title>
          <description>Food stuck and unable to swallow liquids for &gt;5 minutes</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participants with Food Impaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants without Food Impaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Esophageal Eosinophil Count</title>
          <units>eosinophils/high powered field</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="8" upper_limit="100"/>
                    <measurement group_id="B2" value="40" lower_limit="20" upper_limit="80"/>
                    <measurement group_id="B3" value="40" lower_limit="8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Response to Dysphagia</title>
        <description>Measured by the Mayo Dysphagia Questionnaire, a validated 28 item instrument; 0=no dysphagia, higher levels indicate greater dysphagia severity. A complete symptom response was defined as an answer of &quot;no&quot; to the question &quot;In the past 2 weeks, have you had trouble swallowing, not associated with other cold symptoms (such as strep throat or mono)?&quot;</description>
        <time_frame>2 weeks</time_frame>
        <population>Analysis was run per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo inhaler swallowed bid for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response to Dysphagia</title>
          <description>Measured by the Mayo Dysphagia Questionnaire, a validated 28 item instrument; 0=no dysphagia, higher levels indicate greater dysphagia severity. A complete symptom response was defined as an answer of &quot;no&quot; to the question &quot;In the past 2 weeks, have you had trouble swallowing, not associated with other cold symptoms (such as strep throat or mono)?&quot;</description>
          <population>Analysis was run per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Partial or Complete Response to Dysphagia</title>
        <description>Measured by the Mayo Dysphagia Questionnaire, a validated 28 item instrument; 0=no dysphagia, higher levels indicate greater dysphagia severity. A complete symptom response was defined as an answer of &quot;no&quot; to the question &quot;In the past 2 weeks, have you had trouble swallowing, not associated with other cold symptoms (such as strep throat or mono)?&quot; A partial symptom response was defined as an answer of yes to the above question and a decrease in severity of at least 2 levels, or a decrease in frequency of at least 1 level.</description>
        <time_frame>2 weeks</time_frame>
        <population>Analysis was run per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo inhaler swallowed bid for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Partial or Complete Response to Dysphagia</title>
          <description>Measured by the Mayo Dysphagia Questionnaire, a validated 28 item instrument; 0=no dysphagia, higher levels indicate greater dysphagia severity. A complete symptom response was defined as an answer of &quot;no&quot; to the question &quot;In the past 2 weeks, have you had trouble swallowing, not associated with other cold symptoms (such as strep throat or mono)?&quot; A partial symptom response was defined as an answer of yes to the above question and a decrease in severity of at least 2 levels, or a decrease in frequency of at least 1 level.</description>
          <population>Analysis was run per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Histologic Response</title>
        <description>A complete histologic response was defined as &gt;90% decrease in mean eosinophil count/high powered field</description>
        <time_frame>2 weeks</time_frame>
        <population>Analysis was run per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo inhaler swallowed bid for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Histologic Response</title>
          <description>A complete histologic response was defined as &gt;90% decrease in mean eosinophil count/high powered field</description>
          <population>Analysis was run per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <desc>Safety was assessed with the side effect questionnaire at weeks 2 and 4 completed by a structured phone interview. The side effect questionnaire had questions on sore throat, hoarseness, white spots in the mouth, irritability, leg swelling, sleep disturbance, appetite change, acne, headache, diarrhea, nausea, and other new symptoms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fluticasone</title>
          <description>Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo inhaler swallowed bid for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Esophageal candidiasis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The relatively small sample size; unexpected high dropout rate in the placebo group; study commenced before the consensus definition of EoE advising exclusion of gastroesophageal reflux disease (GERD) was established.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey A. Alexander, MD, Assistant Professor of Medicine</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-538-2403</phone>
      <email>alexander.jeffrey14@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

